Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Study acronym: TroFuse-007

StatusRecruiting

PhasePhase 3

SponsorMerck Sharp & Dohme LLC

Started2023-12-15

View on ClinicalTrials.gov ↗

Amendment history

The 50 most recent of 84 record versions are listed below. See every version on ClinicalTrials.gov ↗

2026-09-01

Study Status, Contacts/Locations v83

Study sites220 entries, revised

Centrum Onkologii im. Prof. Franciszka Lukaszczyka~~-Ambulatorium Chemioterapii~~ ( Site 2003)

2026-08-25

Study Status, Study Description, Contacts/Locations v82

Study sitesdetails revised at 1 of 220 sites

2026-07-28

Study Status, Contacts/Locations v81

Study sitesdetails revised at 2 of 220 sites

2026-07-17

Study Status, Contacts/Locations v80

Study sites220 entries, revised

Centre Hospitalier de la ~~Côte~~Cote Basque ( Site 1300)

2026-06-30

Study Status, Contacts/Locations v79

Study sitesdetails revised at 1 of 220 sites

Show 45 earlier versions

2026-06-26

Study Status, Contacts/Locations v78

Study sitesdetails revised at 2 of 220 sites

2026-06-17

Study Status, Contacts/Locations v77

Study sites220 entries, revised

Instytut ~~Gruźlicy~~Gruzlicy i ~~Chorób~~Chorob ~~Płuc~~Pluc w Warszawie~~-3rd Dep of Lung Diseases and Oncology~~ ( Site 2011)

2026-06-11

Study Status, Contacts/Locations v76

Study sites219→220

2026-06-05

Study Status, Contacts/Locations v75

Study sitesdetails revised at 5 of 219 sites

2026-05-27

Study Status, Contacts/Locations v74

Study sites218→219

2026-05-20

Study Status, Contacts/Locations v73

Study sitesdetails revised at 3 of 218 sites

2026-05-13

Study Status, Contacts/Locations v72

Study sitesdetails revised at 2 of 218 sites

2026-05-06

Study Status, Contacts/Locations v71

Study sitesdetails revised at 6 of 218 sites

2026-05-01

Study Status, Contacts/Locations v70

Study sitesdetails revised at 5 of 218 sites

2026-04-24

Study Status, Contacts/Locations v69

Study sitesdetails revised at 5 of 218 sites

2026-04-08

Study Status, Contacts/Locations v68

Study sites218 entries, revised

Saiseikai Matsusaka Municipal Hospital ( Site 3422)

2026-04-01

Study Status, Contacts/Locations v67

Study sites218 entries, revised

Chulalongkorn University~~-Medicine~~ ( Site 4003)

2026-03-25

Study Status, Contacts/Locations v66

Study sites217→218

2026-03-19

Study Status, Contacts/Locations v65

Study sitesdetails revised at 1 of 217 sites

2026-03-12

Study Status, Contacts/Locations v64

Study sitesdetails revised at 5 of 217 sites

2026-03-03

Study Status, Contacts/Locations v63

Study sitesdetails revised at 3 of 217 sites

2026-02-26

Study Status, Contacts/Locations v62

Study sitesdetails revised at 2 of 217 sites

2026-02-18

Study Status, Outcome Measures, Contacts/Locations v61

Study sites215→217

Secondary endpointsdetails revised at 3 of 13 entries

2026-02-03

Study Status, Contacts/Locations v60

Study sitesdetails revised at 1 of 215 sites

2026-01-16

Study Status, Contacts/Locations v59

Study sitesdetails revised at 5 of 215 sites

2026-01-02

Study Status, Contacts/Locations v58

Study sitescontacts updated at 2 of 215 sites

2025-12-23

Study Status, Contacts/Locations v57

Study sites214→215

2025-12-17

Study Status, Contacts/Locations v56

Study sitesdetails revised at 3 of 214 sites

2025-12-10

Study Status, Contacts/Locations v55

Study sites213→214

2025-11-12

Study Status, Contacts/Locations v54

Study sitesdetails revised at 2 of 213 sites

2025-10-29

Study Status, Contacts/Locations v53

Study sites212→213

2025-10-17

Study Status, Contacts/Locations v52

Study sites210→212

2025-10-10

Study Status, Contacts/Locations v51

Study sitescontacts updated at 4 of 210 sites

2025-10-03

Study Status, Contacts/Locations v50

Study sitescontacts updated at 1 of 210 sites

2025-09-25

Study Status, Contacts/Locations v49

Study sitescontacts updated at 3 of 210 sites

2025-09-19

Study Status, Contacts/Locations v48

Study sites209→210

2025-09-09

Study Status, Contacts/Locations v47

Study sites208→209

2025-08-29

Study Status, Contacts/Locations v46

Study sites207→208

2025-08-13

Study Status, Arms and Interventions, Outcome Measures, Eligibility, Contacts/Locations v45

InterventionsPembrolizumab (Biological), Sacituzumab tirumotecan (Biological)→Pembrolizumab (Biological), Sacituzumab tirumotecan (Biological), Supportive care measures (Drug)

Eligibility criteria+7 characters

[...] rome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing. Has ac [...]

Secondary endpointsdetails revised at 13 of 13 entries

Study sites207 entries, revised

~~Ultramar~~Dr. ~~Imaging~~Abdurrahman ~~Center~~Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi-oncology ( Site 2506)

2025-07-25

Study Status, Contacts/Locations v44

Study sitescontacts updated at 4 of 207 sites

2025-07-18

Study Status, Contacts/Locations v43

Study sitesdetails revised at 6 of 207 sites

2025-07-11

Study Status, Contacts/Locations v42

Study sites206→207

2025-07-04

Study Status, Contacts/Locations v41

Study sites205→206

2025-06-26

Study Status, Contacts/Locations v40

Study sitesdetails revised at 6 of 205 sites

2025-06-11

Study Status, Contacts/Locations v39

Study sites204→205

2025-06-06

Study Status, Contacts/Locations v38

Study sites202→204

2025-05-30

Study Status, Contacts/Locations v37

Study sites201→202

2025-05-23

Study Status, Contacts/Locations v36

Study sites201 entries, revised

Southern Medical University Nanfang Hospital-Depatrment of Respiratory and Critical Care Medicine ( Site 3108) FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( ~~Sit~~Site 0600) Centre Hospitalier Universitaire de Limoges - Hôpital Dupuyt-Unité d'oncologie thoracique et cutané ( Site 1303) Universitätsmedizin Johannes Gutenberg Universität Mainz-3. Medizinische Klinik und Poliklinik ( ~~Sit~~Site 1404) Charité Campus Virchow-Klinikum-Department of Infectious Diseases and Pulmonary Medicine ( Site 1402) IRCCS - Istituto Romagnolo per lo Studio dei Tumori [...] [...]

2025-05-08

Study Identification, Study Status, Contacts/Locations v35

Study sitescontacts updated at 5 of 201 sites

2025-04-30

Study Status, Contacts/Locations v34

Study sites184→201

Merck (MSD)

401 trials monitored

See 24 trials at risk

Lung Cancer

4,033 trials monitored

See 210 trials at risk

Non-Small Cell Lung Cancer (NSCLC)

2,914 trials monitored

See 156 trials at risk

The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination of sacituzumab tirumotecan and pembrolizumab is superior to pembrolizumab alone with respect to OS.

Trial Details

NCT Number	NCT06170788
Lead Sponsor	Merck Sharp & Dohme LLC
Conditions	Non-small Cell Lung Cancer (NSCLC)
Enrollment	614 participants
Start Date	2023-12-15
Primary Completion	2028-01-25 (estimated)
Study Completion	2030-05-27 (estimated)
Updated on ClinicalTrials.gov	2026-09-25